ERBB2 and breast carcinoma: There are currently three phase 2/3 clinical trials ongoing in China, in the metastatic setting for HER-2-overexpressing (NCT05263869; NCT04924699) and HER-2-low (NCT04742153) breast cancer (see Table 7).